On January 21, 2020, the U.S. Food and Drug Administration (FDA) approved Tepezza™ (teprotumumab-trbw) for the treatment of adults with Thyroid Eye Disease. This is a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis).
The approval represents the first drug approved for the treatment of thyroid eye disease. DENT Neurologic Institute performed the first infusion in a private practice on February 12, 2020, on Rodney K.
Rodney has agreed to give progress updates for each infusion, and his hopes for the treatment. You can follow Rodney’s real-time progress below.
Infusion #1 – February 12, 2020
“My expectation and hopes are that the bulging is reduced, that the vision is realigned properly, that the double vision is eliminated and that I will be able to see out of my left eye and to be able to read. Overall, I would like better sight out of my left eye. Icing on the cake would be if the shaking in my hands would go away, and all my symptoms will subside so I do not need the surgery. I would like to also not need to take the steroid. I would like to erase the embarrassment of face to face contact. There are times when I want to Photoshop my eyes. I think “is that what I really look like?” This drug is almost like a godsend. IF this drug is effective, if it works, it is almost like a miracle. It is so handy that we live close to a facility like DENT.”
Infusion #2 – March 4, 2020
“The pressure and watering are better. I am hoping that the swelling and proptosis go a little bit down more. The double vision was reduced substantially. I feel like sometimes I still look a little pirate-like. The misalignment is not as pronounced as it was before [the first infusion]. I am just hoping for a little more improvement all the way around. If this drug was not approved, they were talking about surgeries. They said they would have to go in and shave the bone. It would have been really bad. This drug was approved at the perfect time.”